1
|
Severyns T, Kirchgesner J, Lambert J, Thieblemont C, Amiot A, Abitbol V, Treton X, Cazals-Hatem D, Malamut G, Coppo P, Galicier L, Walter-Petrich A, Deau-Fischer B, Besson C, Aparicio T, Beaugerie L, Allez M, Gornet JM. Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study. J Crohns Colitis 2020; 14:1222-1230. [PMID: 32161943 DOI: 10.1093/ecco-jcc/jjaa048] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
BACKGROUND AND AIMS The prognosis of lymphoma that occurs in patients with inflammatory bowel disease [IBD] is poorly known. METHODS A multicentre retrospective cohort analysis was done in seven French tertiary centres from 1999 to 2019. Only lymphoma occurring in patients with previous established diagnosis of IBD were analysed. The primary outcome was progression-free survival at 3 years. RESULTS A total of 52 patients [male 65%, Crohn's disease 79%, median age 48.3 years, median duration of IBD 10.1 years] were included, of whom 37 had been previously exposed to immunosuppressants and/or biologics for at least 3 months and 20 had primary intestinal lymphomas. The lymphoma histological types were: diffuse large B cell lymphomas [N = 17], Hodgkin lymphomas [N = 17], indolent B cell lymphomas [N = 12], and others including T cell lymphomas, mantle cell lymphomas, and unclassifiable B cell lymphoma [N = 6]. The median follow-up after lymphoma was 5.1 years (interquartile range [IQR] 4-7.8). Progression-free survival at 3 years was 85% in the overall population (95% confidence interval [CI] 75%-96%) with no significant difference between the exposed and unexposed group, 79% for patients exposed to immunosuppressants and/or biologics [95% CI 67%-94%], and 83% for patients diagnosed with primary intestinal lymphoma [95% CI 67%-100%]. No relapse of IBD has been observed during chemotherapy. The IBD relapse rate at the end of the last chemotherapy cycle was 23% at 3 years [95% CI 11%-39%] in the overall population. CONCLUSIONS In this large cohort, the prognosis for lymphomas occurring in IBD appears to be good and similar to what is expected, irrespective of the exposure to biologics and/or immunosuppressants.
Collapse
Affiliation(s)
- T Severyns
- Service de Gastroentérologie, Hôpital Saint Louis, Université de Paris, Paris, France
| | - J Kirchgesner
- Service de Gastroentérologie, Hôpital Saint-Antoine, Sorbonne Université, Paris, France
| | - J Lambert
- Service de Biostatistiques et Information Médicale, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - C Thieblemont
- Service d'Hémato-oncologie, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - A Amiot
- Service de Gastroentérologie, Hôpital Henri Mondor, UPEC, Créteil, France
| | - V Abitbol
- Service de Gastroentérologie, Hôpital Cochin, Université de Paris, Paris, France
| | - X Treton
- Service de Gastroentérologie, Hôpital Beaujon, Université de Paris, Clichy La Garenne, France
| | - D Cazals-Hatem
- Département de Pathologie, Hôpital Beaujon, Université de Paris, Clichy La Garenne. France
| | - G Malamut
- Service de Gastroentérologie, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France
| | - P Coppo
- Service d'Hématologie, Hôpital Saint-Antoine, Sorbonne Université, Paris, France
| | - L Galicier
- Service d'Immunohématologie, Hôpital Saint Louis, Université de Paris, Paris, France
| | - A Walter-Petrich
- Service de Biostatistiques et Information Médicale, Hôpital Saint-Louis, Université de Paris, Paris, France
| | - B Deau-Fischer
- Service d'Hématologie, Hôpital Cochin, Université de Paris, Paris, France
| | - C Besson
- Service d'Hématologie-Oncologie, Centre Hospitalier de Versailles, Université Versailles Saint Quentin en Yvelines, Université de Paris-Saclay, Le Chesnay, France
| | - T Aparicio
- Service de Gastroentérologie, Hôpital Saint Louis, Université de Paris, Paris, France
| | - L Beaugerie
- Service de Gastroentérologie, Hôpital Saint-Antoine, Sorbonne Université, Paris, France
| | - M Allez
- Service de Gastroentérologie, Hôpital Saint Louis, Université de Paris, Paris, France
| | - J M Gornet
- Service de Gastroentérologie, Hôpital Saint Louis, Université de Paris, Paris, France
| |
Collapse
|
2
|
Dumas M, Henrion-Charbit F, Rybojad M, Jachiet M, Cordoliani F, Petit A, Pascal F, Flavant A, Bagot M, Cerf-Bensussan N, Malamut G, Bouaziz JD. Caractéristiques cliniques et réponse thérapeutique de la granulomatose oro-faciale. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, Trinquand A, Lhermitte L, Brousse N, Suarez F, Frenzel L, Delarue R, Marçais A, Macintyre E, Asnafi V, Lhospice F, Bonnafous C, Molina T, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O. NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_26] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Cheminant
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - J. Bruneau
- Pathology Department, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - G. Malamut
- Gastroenterology, HEGP Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - D. Sibon
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - N. Guegan
- INSERM UMR1163, Laboratory of Intestinal Immunity; Institut Imagine; Paris France
| | - A. Trinquand
- Biological Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - L. Lhermitte
- Biological Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - N. Brousse
- Pathology Department, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - F. Suarez
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - L. Frenzel
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - R. Delarue
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - A. Marçais
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - E. Macintyre
- Biological Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - V. Asnafi
- Biological Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - F. Lhospice
- Innate Pharma; Innate Pharma; Marseille France
| | | | - T. Molina
- Pathology Department, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - B. Meresse
- INSERM UMR1163, Laboratory of Intestinal Immunity; Institut Imagine; Paris France
| | - C. Cellier
- Gastroenterology, HEGP Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| | - N. Cerf-Bensussan
- INSERM UMR1163, Laboratory of Intestinal Immunity; Institut Imagine; Paris France
| | - O. Hermine
- Clinical Hematology, Necker Hospital; Paris Descartes - Sorbonne Paris Cité University, AP-HP; Paris France
| |
Collapse
|
4
|
Nijeboer P, Malamut G, Mulder CJ, Cerf-Bensussan N, Sibon D, Bouma G, Cellier C, Hermine O, Visser O. Enteropathy-associated T-cell lymphoma: improving treatment strategies. Dig Dis 2015; 33:231-235. [PMID: 25925928 DOI: 10.1159/000369542] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Enteropathy-associated T-cell lymphoma (EATL) is a rare and usually rapidly fatal intestinal T-cell non-Hodgkin lymphoma. It arises from intraepithelial lymphocytes and has a high association with coeliac disease. The high mortality of EATL is associated not only with the very aggressive and often chemotherapy-refractory nature of the lymphoma. The poor condition of patients due to prolonged and severe malnutrition compromises the ability to deliver chemotherapy. There are no standardized treatment protocols, and the optimal therapy for EATL remains unclear. The primary step of treatment consists of local debulking, preferably as early as possible after EATL diagnosis. Morbidity and mortality seem to rise with advanced stages of disease due to tumour size progression, worse nutritional status and a higher risk of emergency surgery due to perforation. Standard induction therapy for EATL is anthracycline-based chemotherapy, preferably resumed between 2 and 5 weeks after surgery (depending on clinical condition). Intensification of therapy using high-dose chemotherapy followed by consolidation with BEAM and autologous stem cell transplantation is associated with better outcome. Notably, this treatment strategy has only been applied in patients eligible for this aggressive regimen which might reflect selection bias. Unfortunately, prognosis of EATL remains poor; 5-year survival varies from 8 to 60% depending on the eligibility to receive additional steps of therapy. New treatment strategies are urgently needed for a better prognosis of this lethal complication of coeliac disease. Brentuximab vedotin (anti-CD30) might be promising when added to conventional chemotherapy and is suggested as upfront treatment in EATL.
Collapse
|
5
|
Marthey L, Cadiot G, Seksik P, Pouderoux P, Lacroute J, Skinazi F, Mesnard B, Chayvialle JA, Savoye G, Druez A, Parlier D, Abitbol V, Gompel M, Eoche M, Poncin E, Bobichon R, Colardelle P, Wils P, Salloum H, Peschard S, Zerbib F, Méresse B, Cerf-Bensussan N, Malamut G, Carbonnel F. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther 2014; 40:1103-9. [PMID: 25199794 DOI: 10.1111/apt.12937] [Citation(s) in RCA: 111] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2014] [Revised: 06/23/2014] [Accepted: 08/08/2014] [Indexed: 12/12/2022]
Abstract
BACKGROUND Recently, a new enteropathy has been described: olmesartan-associated enteropathy. However, the association has been questioned: a phase 3 trial and a cohort study found no association between gastrointestinal events and olmesartan. AIM To collect French cases of sartan-associated enteropathy to describe further this entity, confirm or refute causality, and determine if the association exists with other sartans. METHODS French gastroenterologists were invited to report cases of sartan-associated enteropathy and collect clinical, biological and histological data. Patients with diarrhoea and histological duodenal abnormalities were included. RESULTS Thirty-six patients with olmesartan-associated enteropathy were reported, including 32 with villous atrophy and four without. There was only one patient with irbesartan-associated enteropathy. None of the patients died. Patients with villous atrophy had diarrhoea, vomiting, renal failure, hypokalaemia, body weight loss and hypoalbuminaemia. Thirty-one patients were hospitalised; four required intensive care. Anti-transglutaminase and anti-enterocyte antibodies were negative; anti-nuclear antibodies were positive (9/11). Endoscopic duodenal biopsies showed villous atrophy (32/32) and polyclonal intra-epithelial CD3+CD8+ lymphocytosis (11/11). Exactly, 14/15 patients responded to steroids and/or immunosuppressants, prescribed because of suspected autoimmune enteropathy. Ten olmesartan interruptions were followed by reintroductions before steroids or immunosuppressants. Interruptions were followed by remissions (9/10), but reintroductions were followed by relapses (9/9). Twenty-nine patients were in remission since olmesartan interruption, including 26 without immunosuppressants. Patients with normal villi had similar clinical characteristics, but mild histological abnormalities (intra-epithelial lymphocytosis and lamina propria lymphocytic infiltration). CONCLUSIONS Olmesartan causes a severe and immune-mediated enteropathy, with or without villous atrophy. Enteropathy associated with other sartans seems to be very rare.
Collapse
Affiliation(s)
- L Marthey
- Kremlin Bicêtre University Hospital, Assistance Publique-Hopitaux de Paris (AP-HP), Paris-Sud University, Le Kremlin Bicêtre; Antoine Béclère University Hospital, AP-HP, Paris-Sud University, Clamart, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Prost à la Denise J, Douard R, Malamut G, Mecheri F, Wind P. Small Bowel Obstruction in Patients with a Prior History of Cancer: Predictive Findings of Malignant Origins. World J Surg 2013; 38:363-9. [DOI: 10.1007/s00268-013-2303-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Garnier-Lengliné H, Malamut G, Cerf-Bensussan N, Ruemmele FM. [Treatment perspectives]. Pathol Biol (Paris) 2013; 61:e61-e64. [PMID: 22037405 DOI: 10.1016/j.patbio.2011.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Accepted: 03/23/2011] [Indexed: 05/31/2023]
Abstract
Celiac disease (CD) is a chronic inflammatory enteropathy caused by the ingestion of gluten. A safe and efficient but unpleasant treatment exists for CD in form of a strict gluten-free diet. Thus, there is a need for new treatment strategies, which are based on the improved and advanced understanding of the pathophysiology of CD. The first strategy consists in reducing or even eliminating major antigenic motifs in gluten, responsible for the inflammatory reaction. The use of less immunogenic wheat was suggested but this seems rather difficult to realize. However, a complete digestion of the immunogenic parts of gluten looks very promising. This can be obtained by the use of polymers, capable to sequester gluten proteins or even better via the exogenous administration of propyl-endopeptidases, with two different enzymes under development. Another approach could be the use of inhibitors of tissue transglutaminase, a strategy which is under clinical investigation. Alternatively, inhibition of the site of liaison of immunostimulatory peptides with HLA molecules was suggested and is also under investigation in vivo. For patients suffering from refractory sprue, the inhibition of IL15 might be of therapeutic interest with the hope to improve the fatal outcome of many of these patients. However, the ultimate treatment approach is in form of prevention and the role of infectious agents, such as Rotavirus, in disease onset has to be considered.
Collapse
|
8
|
Moinet F, Lafont E, Avillach P, Cochereau D, Sanchez O, Malamut G, Benoit MO, Ranque B, Pouchot J. Étiologies des hypo-alpha1-globulinémie sur l’électrophorèse des protéines sériques et impact sur le diagnostic de déficit en alpha1-antitrypsine : étude monocentrique rétrospective de 47 cas. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.03.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Saillen E, Naneix A, Canioni D, Bruneval P, Meatchi T, Malamut G, Rahmi G, Capron L, Ranque B, Pouchot J, Cellier C, Georgin-Lavialle S. Œsophagite à éosinophiles chez l’adulte : description d’une série monocentrique de 17 cas. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
10
|
Chandesris MO, Malamut G, Verkarre V, Meresse B, Macintyre E, Delarue R, Rubio MT, Suarez F, Deau-Fischer B, Cerf-Bensussan N, Brousse N, Cellier C, Hermine O. Enteropathy-associated T-cell lymphoma: a review on clinical presentation, diagnosis, therapeutic strategies and perspectives. ACTA ACUST UNITED AC 2010; 34:590-605. [PMID: 21050687 DOI: 10.1016/j.gcb.2010.09.008] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION Enteropathy-associated T-cell lymphoma (EATL) is a rare complication of celiac disease (<1% of lymphomas) and has a poor prognosis. METHODS International literature review with PubMed search (up to January 2009) of pathophysiological, clinical and therapeutic data. RESULTS EATL is found in patients with a mean age of 59 years, often with a complication that signals its diagnosis. Refractory celiac disease (RCD), equivalent to low-grade intraepithelial T-cell lymphoma, could be an intermediary between celiac disease and high-grade invasive T-cell lymphoma. The median survival is 7 months, with no significant difference between stages; the cumulative 5-year survival is less than 20%. The poor prognosis is determined by disease that has often spread before it is diagnosed (50%), multifocal involvement of the small bowel (50%), poor general health status and undernutrition, and recurrence of complications (infections, perforations, gastrointestinal haemorrhages, occlusions), thus delaying the chemotherapy and contributing to frequent chemotherapy resistance. There is currently no effective and consensual treatment: preventive surgery for complications is controversial, and the results of chemotherapy are disappointing. The classic CHOP protocol (combination of doxorubicin-cyclophosphamide-vincristine-prednisone) does not have satisfactory results and survival remains poor, especially in patients with underlying RCD. High-dose chemotherapy with autotransplantion seems to only improve the prognosis in localised forms. Allogeneic bone marrow transplantation was not evaluated. In all, 1/3 of patients, being unfit for treatment, die before 3 months and half of treated patients stop chemotherapy prematurely due to inefficacy, intolerance and/or complications. CONCLUSION Improvement of the prognosis requires collaboration in order to compose a national cohort, to evaluate new diagnostic and therapeutic strategies and to define prognostic factors.
Collapse
Affiliation(s)
- M-O Chandesris
- Service d'hématologie adulte, hôpital Necker-Enfants-Malades, Assistance publique-Hôpitaux de Paris, université Paris V-René-Descartes, 149, rue de Sèvres, 75743 Paris cedex 15, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
Celiac disease is an enteropathy due to gluten intake in genetically predisposed individuals (HLA DQ2/DQ8). Celiac disease occurs in adults and children at rates approaching 1% of population in Europe and USA. Clinical features observed in celiac disease are extremely various and anaemia, oral aphthous stomatis, amenorrhea or articular symptoms may be the only presenting manifestations. Diagnosis relies on the evidence of histological villous atrophy in proximal small bowel and the presence of specific serum antibodies. Treatment relies on eviction of gluten (wheat, barley, rye) from diet. Gluten free diet allows prevention of malignant complications such as small bowel adenocarcinoma and lymphoma, and osteopenia. The main cause of resistance to gluten free diet is its poor observance. If not the case, serious complications of celiac disease, such as clonal refractory celiac sprue and intestinal T-cell lymphoma should be suspected. Current therapeutic challenges concern alternative to gluten free diet and new efficient treatments of lymphomatous complications.
Collapse
Affiliation(s)
- G Malamut
- Université Paris Descartes, 75006 Paris, France.
| | | |
Collapse
|
12
|
|
13
|
Malamut G. [Immunosurveillance: a new prognostic factor in colorectal cancer]. Gastroenterol Clin Biol 2008; 32:1098-1100. [PMID: 19013737 DOI: 10.1016/j.gcb.2008.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Affiliation(s)
- G Malamut
- Service d'hépatogastroentérologie, université Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France.
| |
Collapse
|
14
|
Malamut G, Hermine O, Cellier C. Structuration nationale pour la prise en charge des lymphomes à petites (sprue réfractaire de type II) et grandes cellules associés à la maladie cœliaque. ONCOLOGIE 2008. [DOI: 10.1007/s10269-008-0890-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Malamut G, Matysiak-Budnik T, Grosdider E, Jais JP, Morales E, Damotte D, Caillat-Zucman S, Brousse N, Cerf-Bensussan N, Jian R, Cellier C. Adult celiac disease with severe or partial villous atrophy: a comparative study. ACTA ACUST UNITED AC 2008; 32:236-42. [PMID: 18359595 DOI: 10.1016/j.gcb.2008.02.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND AND AIMS While severe villous atrophy (SVA) is the most typical histological feature in adult celiac disease (ACD), partial villous atrophy (PVA) is now also frequently found. So far, the impact of the severity of villous atrophy on the clinical presentation of ACD has been scarcely investigated. We aimed to compare the clinical, biological and immune features and outcomes in ACD patients presenting with PVA at diagnosis versus patients with SVA. PATIENTS AND METHODS Medical files of 48 patients with ACD diagnosed between 1992 and 2003 were retrospectively studied. The diagnosis was based on the presence of intestinal villous atrophy, with increases in intraepithelial lymphocytes and circulating celiac specific antibodies. Villous atrophy was classified as severe (subtotal and total) or partial. Symptoms, biological signs of malabsorption, immune markers, bone mineral density at diagnosis and response to gluten-free diet were recorded. RESULTS At diagnosis, ten patients (four M/six F) had PVA and 38 patients (five M/33 F) had SVA, with a median age of 54 and 33 years, respectively (p<0.05). Positivity for specific antibodies, HLA typing and frequency of autoimmune disease at diagnosis were similar in both PVA and SVA patients, as was their response to gluten-free diet. Diarrhea, malabsorption syndrome and osteopenia were independent of the degree of villous atrophy. CONCLUSION PVA was observed in 21% of patients with ACD. Except for their older age at diagnosis, patients with PVA presented with similar clinical, biological and immune characteristics and outcomes as did patients with SVA.
Collapse
Affiliation(s)
- G Malamut
- Department of Gastroenterology and Hepatology, hôpital européen Georges-Pompidou, 75015 Paris, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Affiliation(s)
- G Malamut
- Service d'Hépatogastroentérologie, Hôpital Européen Georges-Pompidou, 20 Rue Leblanc, 75015 Paris, France.
| |
Collapse
|
17
|
Malamut G, Perlemuter G, Buffet C, Bedossa P, Joly JP, Colombat M, Kuoch V, Pelletier G. [Epithelioid hemangioendothelioma associated with nodular regenerative hyperplasia]. Gastroenterol Clin Biol 2001; 25:1105-7. [PMID: 11910993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/18/2023]
Abstract
Epithelioid hemangioendothelioma of the liver is a rare neoplasm of vascular origin. We report a case of epithelioid hemangioendothelioma occurring in a patient with nodular regenerative hyperplasia. This association suggests that some hepatic vascular changes might promote the growth of epithelioid hemangioendothelioma.
Collapse
Affiliation(s)
- G Malamut
- Service des Maladies du Foie et de l'Appareil Digestif Hôpital de Bicêtre, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Maroteaux P, Malamut G. [Acrodysostosis]. Presse Med (1893) 1968; 76:2189-92. [PMID: 5305130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|